

“Assessing the quality of reporting of observational studies in cancer”

All papers included in final analysis

1. Adams KF, Leitzmann MF, Albanes D, et al. Body mass and colorectal cancer risk in the NIH-AARP cohort. *Am J Epidemiol* 2007;166:36-45.
2. Anderson JP, Ross JA, Folsom AR. Anthropometric variables, physical activity, and incidence of ovarian cancer: The Iowa Women's Health Study. *Cancer* 2004;100:1515-21.
3. Andersson SO, Wolk A, Bergstrom R, et al. Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers. *J Natl Cancer Inst* 1997;89:385-9.
4. Baanders-van Halewijn EA, Poortman J. A case-control study of endometrial cancer within a cohort. *Maturitas* 1985;7:69-76.
5. Barrett-Connor E, Friedlander NJ. Dietary fat, calories, and the risk of breast cancer in postmenopausal women: a prospective population-based study. *J Am Coll Nutr* 1993;12:390-9.
6. Bernstein L, Deapen D, Cerhan JR, et al. Tamoxifen therapy for breast cancer and endometrial cancer risk. *J Natl Cancer Inst* 1999;91:1654-62.
7. Birmann BM, Giovannucci E, Rosner B, et al. Body mass index, physical activity, and risk of multiple myeloma. *Cancer Epidemiol Biomarkers Prev* 2007;16:1474-8.
8. Bjorge T, Engeland A, Tretli S, et al. Body size in relation to cancer of the uterine corpus in 1 million Norwegian women. *Int J Cancer* 2007;120:378-83.
9. Bjorge T, Tretli S, Engeland A. Relation of height and body mass index to renal cell carcinoma in two million Norwegian men and women. *Am J Epidemiol* 2004;160:1168-76.
10. Blair CK, Cerhan JR, Folsom AR, et al. Anthropometric characteristics and risk of multiple myeloma. *Epidemiology* 2005;16:691-4.
11. Bostick RM, Potter JD, Kushi LH, et al. Sugar, meat, and fat intake, and non-dietary risk factors for colon cancer incidence in Iowa women (United States). *Cancer Causes Control* 1994;5:38-52.
12. Bowers K, Albanes D, Limburg P, et al. A prospective study of anthropometric and clinical measurements associated with insulin resistance syndrome and colorectal cancer in male smokers. *Am J Epidemiol* 2006;164:652-64.
13. Cerhan JR, Janney CA, Vachon CM, et al. Anthropometric characteristics, physical activity, and risk of non-Hodgkin's lymphoma subtypes and B-cell chronic lymphocytic leukemia: a prospective study. *Am J Epidemiol* 2002;156:527-35.
14. Cerhan JR, Torner JC, Lynch CF, et al. Association of smoking, body mass, and physical activity with risk of prostate cancer in the Iowa 65+ Rural Health Study (United States). *Cancer Causes Control* 1997;8:229-38.
15. Chang SC, Lacey JV, Jr., Brinton LA, et al. Lifetime weight history and endometrial cancer risk by type of menopausal hormone use in the NIH-AARP diet and health study. *Cancer Epidemiol Biomarkers Prev* 2007;16:723-30.
16. Chang SC, Ziegler RG, Dunn B, et al. Association of energy intake and energy balance with postmenopausal breast cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. *Cancer Epidemiol Biomarkers Prev* 2006;15:334-41.

17. Chyou PH, Nomura AM, Stemmermann GN. A prospective study of weight, body mass index and other anthropometric measurements in relation to site-specific cancers. *Int J Cancer* 1994;57:313-7.
18. Chyou PH, Nomura AM, Stemmermann GN. A prospective study of colon and rectal cancer among Hawaii Japanese men. *Ann Epidemiol* 1996;6:276-82.
19. De Stavola BL, Wang DY, Allen DS, et al. The association of height, weight, menstrual and reproductive events with breast cancer: results from two prospective studies on the island of Guernsey (United Kingdom). *Cancer Causes Control* 1993;4:331-40.
20. Engeland A, Tretli S, Akslen LA, et al. Body size and thyroid cancer in two million Norwegian men and women. *Br J Cancer* 2006;95:366-70.
21. Engeland A, Tretli S, Austad G, et al. Height and body mass index in relation to colorectal and gallbladder cancer in two million Norwegian men and women. *Cancer Causes Control* 2005;16:987-96.
22. Engeland A, Tretli S, Bjorge T. Height, body mass index, and ovarian cancer: a follow-up of 1.1 million Norwegian women. *J Natl Cancer Inst* 2003;95:1244-8.
23. Engeland A, Tretli S, Bjorge T. Height, body mass index, and prostate cancer: a follow-up of 950000 Norwegian men. *Br J Cancer* 2003;89:1237-42.
24. Engeland A, Tretli S, Bjorge T. Height and body mass index in relation to esophageal cancer; 23-year follow-up of two million Norwegian men and women. *Cancer Causes Control* 2004;15:837-43.
25. Engeland A, Tretli S, Hansen S, et al. Height and body mass index and risk of lymphohematopoietic malignancies in two million Norwegian men and women. *Am J Epidemiol* 2007;165:44-52.
26. Fairfield KM, Willett WC, Rosner BA, et al. Obesity, weight gain, and ovarian cancer. *Obstet Gynecol* 2002;100:288-96.
27. Feigelson HS, Jonas CR, Teras LR, et al. Weight gain, body mass index, hormone replacement therapy, and postmenopausal breast cancer in a large prospective study. *Cancer Epidemiol Biomarkers Prev* 2004;13:220-4.
28. Fernberg P, Odenbro A, Bellocco R, et al. Tobacco use, body mass index and the risk of malignant lymphomas--a nationwide cohort study in Sweden. *Int J Cancer* 2006;118:2298-302.
29. Fernberg P, Odenbro A, Bellocco R, et al. Tobacco use, body mass index, and the risk of leukemia and multiple myeloma: a nationwide cohort study in Sweden. *Cancer Res* 2007;67:5983-6.
30. Finkle WD, McLaughlin JK, Rasgon SA, et al. Increased risk of renal cell cancer among women using diuretics in the United States. *Cancer Causes Control* 1993;4:555-8.
31. Fitzpatrick AL, Daling JR, Furberg CD, et al. Hypertension, heart rate, use of antihypertensives, and incident prostate cancer. *Ann Epidemiol* 2001;11:534-42.
32. Flaherty KT, Fuchs CS, Colditz GA, et al. A prospective study of body mass index, hypertension, and smoking and the risk of renal cell carcinoma (United States). *Cancer Causes Control* 2005;16:1099-106.
33. Ford ES. Body mass index and colon cancer in a national sample of adult US men and women. *Am J Epidemiol* 1999;150:390-8.
34. Freedman DM, Sigurdson A, Doody MM, et al. Risk of melanoma in relation to smoking, alcohol intake, and other factors in a large occupational cohort. *Cancer Causes Control* 2003;14:847-57.

35. Friedenreich C, Cust A, Lahmann PH, et al. Anthropometric factors and risk of endometrial cancer: the European prospective investigation into cancer and nutrition. *Cancer Causes Control* 2007;18:399-413.
36. Friedman GD, Herrinton LJ. Obesity and multiple myeloma. *Cancer Causes Control* 1994;5:479-83.
37. Furberg AS, Thune I. Metabolic abnormalities (hypertension, hyperglycemia and overweight), lifestyle (high energy intake and physical inactivity) and endometrial cancer risk in a Norwegian cohort. *Int J Cancer* 2003;104:669-76.
38. Gaard M, Tretli S, Urdal P. Blood lipid and lipoprotein levels and the risk of cancer of the colon and rectum. A prospective study of 62,173 Norwegian men and women. *Scand J Gastroenterol* 1997;32:162-8.
39. Galanis DJ, Kolonel LN, Lee J, et al. Anthropometric predictors of breast cancer incidence and survival in a multi-ethnic cohort of female residents of Hawaii, United States. *Cancer Causes Control* 1998;9:217-24.
40. Gamble JF, Pearlman ED, Nicolich MJ. A nested case-control study of kidney cancer among refinery/petrochemical workers. *Environ Health Perspect* 1996;104:642-50.
41. Giovannucci E, Rimm EB, Stampfer MJ, et al. Height, body weight, and risk of prostate cancer. *Cancer Epidemiol Biomarkers Prev* 1997;6:557-63.
42. Gong Z, Neuhauser ML, Goodman PJ, et al. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. *Cancer Epidemiol Biomarkers Prev* 2006;15:1977-83.
43. Habel LA, Van Den Eeden SK, Friedman GD. Body size, age at shaving initiation, and prostate cancer in a large, multiracial cohort. *Prostate* 2000;43:136-43.
44. Hiatt RA, Tolan K, Quesenberry CP, Jr. Renal cell carcinoma and thiazide use: a historical, case-control study (California, USA). *Cancer Causes Control* 1994;5:319-25.
45. Huang Z, Hankinson SE, Colditz GA, et al. Dual effects of weight and weight gain on breast cancer risk. *JAMA* 1997;278:1407-11.
46. Iwasaki M, Otani T, Inoue M, et al. Body size and risk for breast cancer in relation to estrogen and progesterone receptor status in Japan. *Ann Epidemiol* 2007;17:304-12.
47. Jumaan AO, Holmberg L, Zack M, et al. Beta-carotene intake and risk of postmenopausal breast cancer. *Epidemiology* 1999;10:49-53.
48. Kaaks R, Toniolo P, Akhmedkhanov A, et al. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. *J Natl Cancer Inst* 2000;92:1592-600.
49. Kaaks R, Van Noord PA, Den Tonkelaar I, et al. Breast-cancer incidence in relation to height, weight and body-fat distribution in the Dutch "DOM" cohort. *Int J Cancer* 1998;76:647-51.
50. Kanashiki M, Sairenchi T, Saito Y, et al. Body mass index and lung cancer: a case-control study of subjects participating in a mass-screening program. *Chest* 2005;128:1490-6.
51. Kark JD, Yaari S, Rasooly I, et al. Are lean smokers at increased risk of lung cancer? The Israel Civil Servant Cancer Study. *Arch Intern Med* 1995;155:2409-16.
52. Knekt P, Heliovaara M, Rissanen A, et al. Leanness and lung-cancer risk. *Int J Cancer* 1991;49:208-13.
53. Knekt P, Raitasalo R, Heliovaara M, et al. Elevated lung cancer risk among persons with depressed mood. *Am J Epidemiol* 1996;144:1096-103.

54. Krebs EE, Taylor BC, Cauley JA, et al. Measures of adiposity and risk of breast cancer in older postmenopausal women. *J Am Geriatr Soc* 2006;54:63-9.
55. Kurahashi N, Iwasaki M, Sasazuki S, et al. Association of body mass index and height with risk of prostate cancer among middle-aged Japanese men. *Br J Cancer* 2006;94:740-2.
56. Kuriyama S, Tsubono Y, Hozawa A, et al. Obesity and risk of cancer in Japan. *Int J Cancer* 2005;113:148-57.
57. Lacey JV, Jr., Brinton LA, Lubin JH, et al. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women. *Cancer Epidemiol Biomarkers Prev* 2005;14:1724-31.
58. Lacey JV, Jr., Leitzmann M, Brinton LA, et al. Weight, height, and body mass index and risk for ovarian cancer in a cohort study. *Ann Epidemiol* 2006;16:869-76.
59. Lahmann PH, Hoffmann K, Allen N, et al. Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer And Nutrition (EPIC). *Int J Cancer* 2004;111:762-71.
60. Lahmann PH, Lissner L, Gullberg B, et al. A prospective study of adiposity and postmenopausal breast cancer risk: the Malmo Diet and Cancer Study. *Int J Cancer* 2003;103:246-52.
61. Larsson SC, Friberg E, Wolk A. Carbohydrate intake, glycemic index and glycemic load in relation to risk of endometrial cancer: A prospective study of Swedish women. *Int J Cancer* 2007;120:1103-7.
62. Larsson SC, Permert J, Hakansson N, et al. Overall obesity, abdominal adiposity, diabetes and cigarette smoking in relation to the risk of pancreatic cancer in two Swedish population-based cohorts. *Br J Cancer* 2005;93:1310-5.
63. Larsson SC, Rutegard J, Bergkvist L, et al. Physical activity, obesity, and risk of colon and rectal cancer in a cohort of Swedish men. *Eur J Cancer* 2006;42:2590-7.
64. Le Marchand L, Kolonel LN, Wilkens LR, et al. Animal fat consumption and prostate cancer: a prospective study in Hawaii. *Epidemiology* 1994;5:276-82.
65. Le Marchand L, Wilkens LR, Mi MP. Obesity in youth and middle age and risk of colorectal cancer in men. *Cancer Causes Control* 1992;3:349-54.
66. Lee IM, Paffenbarger RS, Jr. Quetelet's index and risk of colon cancer in college alumni. *J Natl Cancer Inst* 1992;84:1326-31.
67. Lee IM, Sesso HD, Paffenbarger RS, Jr. A prospective cohort study of physical activity and body size in relation to prostate cancer risk (United States). *Cancer Causes Control* 2001;12:187-93.
68. Lin J, Zhang SM, Cook NR, et al. Body mass index and risk of colorectal cancer in women (United States). *Cancer Causes Control* 2004;15:581-9.
69. Lindblad M, Rodriguez LA, Lagergren J. Body mass, tobacco and alcohol and risk of esophageal, gastric cardia, and gastric non-cardia adenocarcinoma among men and women in a nested case-control study. *Cancer Causes Control* 2005;16:285-94.
70. Lindgren A, Pukkala E, Nissinen A, et al. Blood pressure, smoking, and the incidence of lung cancer in hypertensive men in North Karelia, Finland. *Am J Epidemiol* 2003;158:442-7.
71. Littman AJ, White E, Kristal AR. Anthropometrics and prostate cancer risk. *Am J Epidemiol* 2007;165:1271-9.
72. Lukanova A, Bjor O, Kaaks R, et al. Body mass index and cancer: results from the Northern Sweden Health and Disease Cohort. *Int J Cancer* 2006;118:458-66.

73. Lukanova A, Toniolo P, Lundin E, et al. Body mass index in relation to ovarian cancer: a multi-centre nested case-control study. *Int J Cancer* 2002;99:603-8.
74. Lundqvist E, Kaprio J, Verkasalo PK, et al. Co-twin control and cohort analyses of body mass index and height in relation to breast, prostate, ovarian, corpus uteri, colon and rectal cancer among Swedish and Finnish twins. *Int J Cancer* 2007;121:810-8.
75. Luo J, Iwasaki M, Inoue M, et al. Body mass index, physical activity and the risk of pancreatic cancer in relation to smoking status and history of diabetes: a large-scale population-based cohort study in Japan--the JPHC study. *Cancer Causes Control* 2007;18:603-12.
76. Luo J, Margolis KL, Adami HO, et al. Body size, weight cycling, and risk of renal cell carcinoma among postmenopausal women: the Women's Health Initiative (United States). *Am J Epidemiol* 2007;166:752-9.
77. MacInnis RJ, English DR, Gertig DM, et al. Body size and composition and prostate cancer risk. *Cancer Epidemiol Biomarkers Prev* 2003;12:1417-21.
78. Macinnis RJ, English DR, Gertig DM, et al. Body size and composition and risk of postmenopausal breast cancer. *Cancer Epidemiol Biomarkers Prev* 2004;13:2117-25.
79. MacInnis RJ, English DR, Haydon AM, et al. Body size and composition and risk of rectal cancer (Australia). *Cancer Causes Control* 2006;17:1291-7.
80. MacInnis RJ, English DR, Hopper JL, et al. Body size and composition and colon cancer risk in women. *Int J Cancer* 2006;118:1496-500.
81. MacInnis RJ, English DR, Hopper JL, et al. Body size and composition and the risk of gastric and oesophageal adenocarcinoma. *Int J Cancer* 2006;118:2628-31.
82. MacInnis RJ, English DR, Hopper JL, et al. Body size and composition and colon cancer risk in men. *Cancer Epidemiol Biomarkers Prev* 2004;13:553-9.
83. Manjer J, Kaaks R, Riboli E, et al. Risk of breast cancer in relation to anthropometry, blood pressure, blood lipids and glucose metabolism: a prospective study within the Malmo Preventive Project. *Eur J Cancer Prev* 2001;10:33-42.
84. Maskarinec G, Erber E, Gill J, et al. Overweight and obesity at different times in life as risk factors for non-Hodgkin's lymphoma: the multiethnic cohort. *Cancer Epidemiol Biomarkers Prev* 2008;17:196-203.
85. McCullough ML, Patel AV, Patel R, et al. Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype. *Cancer Epidemiol Biomarkers Prev* 2008;17:73-9.
86. Mellekjaer L, Bigaard J, Tjonneland A, et al. Body composition and breast cancer in postmenopausal women: a Danish prospective cohort study. *Obesity (Silver Spring)* 2006;14:1854-62.
87. Michaud DS, Giovannucci E, Willett WC, et al. Physical activity, obesity, height, and the risk of pancreatic cancer. *JAMA* 2001;286:921-9.
88. Michels KB, Terry KL, Willett WC. Longitudinal study on the role of body size in premenopausal breast cancer. *Arch Intern Med* 2006;166:2395-402.
89. Mills PK, Beeson WL, Phillips RL, et al. Dietary habits and breast cancer incidence among Seventh-day Adventists. *Cancer* 1989;64:582-90.
90. Mills PK, Beeson WL, Phillips RL, et al. Cohort study of diet, lifestyle, and prostate cancer in Adventist men. *Cancer* 1989;64:598-604.

91. Moore LL, Bradlee ML, Singer MR, et al. BMI and waist circumference as predictors of lifetime colon cancer risk in Framingham Study adults. *Int J Obes Relat Metab Disord* 2004;28:559-67.
92. Morimoto LM, White E, Chen Z, et al. Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). *Cancer Causes Control* 2002;13:741-51.
93. Nicodemus KK, Sweeney C, Folsom AR. Evaluation of dietary, medical and lifestyle risk factors for incident kidney cancer in postmenopausal women. *Int J Cancer* 2004;108:115-21.
94. Nilsen TI, Vatten LJ. Anthropometry and prostate cancer risk: a prospective study of 22,248 Norwegian men. *Cancer Causes Control* 1999;10:269-75.
95. Niwa Y, Yatsuya H, Tamakoshi K, et al. Relationship between body mass index and the risk of ovarian cancer in the Japanese population: findings from the Japanese Collaborate Cohort (JACC) study. *J Obstet Gynaecol Res* 2005;31:452-8.
96. Nothlings U, Wilkens LR, Murphy SP, et al. Body mass index and physical activity as risk factors for pancreatic cancer: the Multiethnic Cohort Study. *Cancer Causes Control* 2007;18:165-75.
97. Oh SW, Yoon YS, Shin SA. Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. *J Clin Oncol* 2005;23:4742-54.
98. Olson JE, Yang P, Schmitz K, et al. Differential association of body mass index and fat distribution with three major histologic types of lung cancer: evidence from a cohort of older women. *Am J Epidemiol* 2002;156:606-15.
99. Olson SH, Trevisan M, Marshall JR, et al. Body mass index, weight gain, and risk of endometrial cancer. *Nutr Cancer* 1995;23:141-9.
100. Otani T, Iwasaki M, Inoue M. Body mass index, body height, and subsequent risk of colorectal cancer in middle-aged and elderly Japanese men and women: Japan public health center-based prospective study. *Cancer Causes Control* 2005;16:839-50.
101. Palmer JR, Adams-Campbell LL, Boggs DA, et al. A prospective study of body size and breast cancer in black women. *Cancer Epidemiol Biomarkers Prev* 2007;16:1795-802.
102. Patel AV, Rodriguez C, Bernstein L, et al. Obesity, recreational physical activity, and risk of pancreatic cancer in a large U.S. Cohort. *Cancer Epidemiol Biomarkers Prev* 2005;14:459-66.
103. Pischon T, Lahmann PH, Boeing H, et al. Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). *J Natl Cancer Inst* 2006;98:920-31.
104. Pischon T, Lahmann PH, Boeing H, et al. Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC). *Int J Cancer* 2006;118:728-38.
105. Putnam SD, Cerhan JR, Parker AS, et al. Lifestyle and anthropometric risk factors for prostate cancer in a cohort of Iowa men. *Ann Epidemiol* 2000;10:361-9.
106. Rapp K, Schroeder J, Klenk J, et al. Obesity and incidence of cancer: a large cohort study of over 145,000 adults in Austria. *Br J Cancer* 2005;93:1062-7.
107. Reeves GK, Pirie K, Beral V, et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. *BMJ* 2007;335:1134.

108. Rodriguez C, Freedland SJ, Deka A, et al. Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. *Cancer Epidemiol Biomarkers Prev* 2007;16:63-9.
109. Ross JA, Parker E, Blair CK, et al. Body mass index and risk of leukemia in older women. *Cancer Epidemiol Biomarkers Prev* 2004;13:1810-3.
110. Samanic C, Chow WH, Gridley G, et al. Relation of body mass index to cancer risk in 362,552 Swedish men. *Cancer Causes Control* 2006;17:901-9.
111. Schouten LJ, Goldbohm RA, van den Brandt PA. Height, weight, weight change, and ovarian cancer risk in the Netherlands cohort study on diet and cancer. *Am J Epidemiol* 2003;157:424-33.
112. Schouten LJ, Goldbohm RA, van den Brandt PA. Anthropometry, physical activity, and endometrial cancer risk: results from the Netherlands Cohort Study. *J Natl Cancer Inst* 2004;96:1635-8.
113. Schuurman AG, Goldbohm RA, Dorant E, et al. Anthropometry in relation to prostate cancer risk in the Netherlands Cohort Study. *Am J Epidemiol* 2000;151:541-9.
114. Sellers TA, Davis J, Cerhan JR, et al. Interaction of waist/hip ratio and family history on the risk of hormone receptor-defined breast cancer in a prospective study of postmenopausal women. *Am J Epidemiol* 2002;155:225-33.
115. Setiawan VW, Pike MC, Kolonel LN, et al. Racial/ethnic differences in endometrial cancer risk: the multiethnic cohort study. *Am J Epidemiol* 2007;165:262-70.
116. Setiawan VW, Stram DO, Nomura AM, et al. Risk factors for renal cell cancer: the multiethnic cohort. *Am J Epidemiol* 2007;166:932-40.
117. Severson RK, Grove JS, Nomura AM, et al. Body mass and prostatic cancer: a prospective study. *BMJ* 1988;297:713-5.
118. Shimizu N, Nagata C, Shimizu H, et al. Height, weight, and alcohol consumption in relation to the risk of colorectal cancer in Japan: a prospective study. *Br J Cancer* 2003;88:1038-43.
119. Silvera SA, Jain M, Howe GR, et al. Energy balance and breast cancer risk: a prospective cohort study. *Breast Cancer Res Treat* 2006;97:97-106.
120. Silvera SA, Rohan TE, Jain M, et al. Glycaemic index, glycaemic load and risk of endometrial cancer: a prospective cohort study. *Public Health Nutr* 2005;8:912-9.
121. Singh PN, Fraser GE. Dietary risk factors for colon cancer in a low-risk population. *Am J Epidemiol* 1998;148:761-74.
122. Sinner PJ, Schmitz KH, Anderson KE, et al. Lack of association of physical activity and obesity with incident pancreatic cancer in elderly women. *Cancer Epidemiol Biomarkers Prev* 2005;14:1571-3.
123. Sjødahl K, Jia C, Vatten L, et al. Body mass and physical activity and risk of gastric cancer in a population-based cohort study in Norway. *Cancer Epidemiol Biomarkers Prev* 2008;17:135-40.
124. Sonnenschein E, Toniolo P, Terry MB, et al. Body fat distribution and obesity in pre- and postmenopausal breast cancer. *Int J Epidemiol* 1999;28:1026-31.
125. Stolzenberg-Solomon RZ, Pietinen P, Taylor PR, et al. A prospective study of medical conditions, anthropometry, physical activity, and pancreatic cancer in male smokers (Finland). *Cancer Causes Control* 2002;13:417-26.
126. Suzuki R, Rylander-Rudqvist T, Ye W, et al. Body weight and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status among Swedish women: A prospective cohort study. *Int J Cancer* 2006;119:1683-9.

127. Tehard B, Clavel-Chapelon F. Several anthropometric measurements and breast cancer risk: results of the E3N cohort study. *Int J Obes (Lond)* 2006;30:156-63.
128. Terry PD, Miller AB, Rohan TE. Obesity and colorectal cancer risk in women. *Gut* 2002;51:191-4.
129. Thompson MM, Garland C, Barrett-Connor E, et al. Heart disease risk factors, diabetes, and prostatic cancer in an adult community. *Am J Epidemiol* 1989;129:511-7.
130. Thune I, Lund E. Physical activity and risk of colorectal cancer in men and women. *Br J Cancer* 1996;73:1134-40.
131. Thune I, Olsen A, Albrektsen G, et al. Cutaneous malignant melanoma: association with height, weight and body-surface area. a prospective study in Norway. *Int J Cancer* 1993;55:555-61.
132. Tornberg SA, Carstensen JM. Relationship between Quetelet's index and cancer of breast and female genital tract in 47,000 women followed for 25 years. *Br J Cancer* 1994;69:358-61.
133. Tulinius H, Sigfusson N, Sigvaldason H, et al. Risk factors for malignant diseases: a cohort study on a population of 22,946 Icelanders. *Cancer Epidemiol Biomarkers Prev* 1997;6:863-73.
134. van den Brandt PA, Dirx MJ, Ronckers CM, et al. Height, weight weight change, and postmenopausal breast cancer risk: The Netherlands Cohort Study. *Cancer Causes Control* 1997;8:39-47.
135. Vatten LJ, Kvinnsland S. Prospective study of height, body mass index and risk of breast cancer. *Acta Oncol* 1992;31:195-200.
136. Veierod MB, Laake P, Thelle DS. Dietary fat intake and risk of prostate cancer: a prospective study of 25,708 Norwegian men. *Int J Cancer* 1997;73:634-8.
137. Verhage BA, Schouten LJ, Goldbohm RA, et al. Anthropometry and pancreatic cancer risk: an illustration of the importance of microscopic verification. *Cancer Epidemiol Biomarkers Prev* 2007;16:1449-54.
138. Wei EK, Giovannucci E, Wu K, et al. Comparison of risk factors for colon and rectal cancer. *Int J Cancer* 2004;108:433-42.
139. Weiderpass E, Braaten T, Magnusson C, et al. A prospective study of body size in different periods of life and risk of premenopausal breast cancer. *Cancer Epidemiol Biomarkers Prev* 2004;13:1121-7.
140. Wright ME, Chang SC, Schatzkin A, et al. Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. *Cancer* 2007;109:675-84.
141. Wu MH, Chou YC, Yu JC, et al. Hormonal and body-size factors in relation to breast cancer risk: a prospective study of 11,889 women in a low-incidence area. *Ann Epidemiol* 2006;16:223-9.
142. Yong LC, Brown CC, Schatzkin A, et al. Prospective study of relative weight and risk of breast cancer: the Breast Cancer Detection Demonstration Project follow-up study, 1979 to 1987-1989. *Am J Epidemiol* 1996;143:985-95.
143. Zhang S, Hunter DJ, Rosner BA, et al. Dietary fat and protein in relation to risk of non-Hodgkin's lymphoma among women. *J Natl Cancer Inst* 1999;91:1751-8.
144. Allen NE, Sauvaget C, Roddam AW, et al. A prospective study of diet and prostate cancer in Japanese men. *Cancer Causes Control* 2004;15:911-20.
145. Andersson SO, Baron J, Wolk A, et al. Early life risk factors for prostate cancer: a population-based case-control study in Sweden. *Cancer Epidemiol Biomarkers Prev* 1995;4:187-92.

146. Berndt SI, Carter HB, Landis PK, et al. Calcium intake and prostate cancer risk in a long-term aging study: the Baltimore Longitudinal Study of Aging. *Urology* 2002;60:1118-23.
147. Bosetti C, Micelotta S, Dal Maso L, et al. Food groups and risk of prostate cancer in Italy. *Int J Cancer* 2004;110:424-8.
148. Chan JM, Giovannucci E, Andersson SO, et al. Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden). *Cancer Causes Control* 1998;9:559-66.
149. Chan JM, Holick CN, Leitzmann MF, et al. Diet after diagnosis and the risk of prostate cancer progression, recurrence, and death (United States). *Cancer Causes Control* 2006;17:199-208.
150. Chan JM, Stampfer MJ, Ma J, et al. Dairy products, calcium, and prostate cancer risk in the Physicians' Health Study. *Am J Clin Nutr* 2001;74:549-54.
151. De Stefani E, Fierro L, Barrios E, et al. Tobacco, alcohol, diet and risk of prostate cancer. *Tumori* 1995;81:315-20.
152. Deneo-Pellegrini H, De Stefani E, Ronco A, et al. Foods, nutrients and prostate cancer: a case-control study in Uruguay. *Br J Cancer* 1999;80:591-7.
153. Ewings P, Bowie C. A case-control study of cancer of the prostate in Somerset and east Devon. *Br J Cancer* 1996;74:661-6.
154. Giovannucci E, Liu Y, Stampfer MJ, et al. A prospective study of calcium intake and incident and fatal prostate cancer. *Cancer Epidemiol Biomarkers Prev* 2006;15:203-10.
155. Giovannucci E, Rimm EB, Colditz GA, et al. A prospective study of dietary fat and risk of prostate cancer. *J Natl Cancer Inst* 1993;85:1571-9.
156. Gronberg H, Damber L, Damber JE. Total food consumption and body mass index in relation to prostate cancer risk: a case-control study in Sweden with prospectively collected exposure data. *J Urol* 1996;155:969-74.
157. Hodge AM, English DR, McCredie MR, et al. Foods, nutrients and prostate cancer. *Cancer Causes Control* 2004;15:11-20.
158. Hsing AW, McLaughlin JK, Schuman LM, et al. Diet, tobacco use, and fatal prostate cancer: results from the Lutheran Brotherhood Cohort Study. *Cancer Res* 1990;50:6836-40.
159. Jain MG, Hislop GT, Howe GR, et al. Plant foods, antioxidants, and prostate cancer risk: findings from case-control studies in Canada. *Nutr Cancer* 1999;34:173-84.
160. Kesse E, Bertrais S, Astorg P, et al. Dairy products, calcium and phosphorus intake, and the risk of prostate cancer: results of the French prospective SU.VI.MAX (Supplémentation en Vitamines et Minéraux Antioxydants) study. *Br J Nutr* 2006;95:539-45.
161. Koh KA, Sesso HD, Paffenbarger RS, Jr., et al. Dairy products, calcium and prostate cancer risk. *Br J Cancer* 2006;95:1582-5.
162. Kristal AR, Cohen JH, Qu P, et al. Associations of energy, fat, calcium, and vitamin D with prostate cancer risk. *Cancer Epidemiol Biomarkers Prev* 2002;11:719-25.
163. Kristal AR, Stanford JL, Cohen JH, et al. Vitamin and mineral supplement use is associated with reduced risk of prostate cancer. *Cancer Epidemiol Biomarkers Prev* 1999;8:887-92.
164. La Vecchia C, Negri E, D'Avanzo B, et al. Dairy products and the risk of prostatic cancer. *Oncology* 1991;48:406-10.
165. Leitzmann MF, Stampfer MJ, Michaud DS, et al. Dietary intake of n-3 and n-6 fatty acids and the risk of prostate cancer. *Am J Clin Nutr* 2004;80:204-16.
166. Mettlin C, Selenskas S, Natarajan N, et al. Beta-carotene and animal fats and their relationship to prostate cancer risk. A case-control study. *Cancer* 1989;64:605-12.

167. Michaud DS, Augustsson K, Rimm EB, et al. A prospective study on intake of animal products and risk of prostate cancer. *Cancer Causes Control* 2001;12:557-67.
168. Mishina T, Watanabe H, Araki H, et al. Epidemiological study of prostatic cancer by matched-pair analysis. *Prostate* 1985;6:423-36.
169. Mitrou PN, Albanes D, Weinstein SJ, et al. A prospective study of dietary calcium, dairy products and prostate cancer risk (Finland). *Int J Cancer* 2007;120:2466-73.
170. Ohno Y, Yoshida O, Oishi K, et al. Dietary beta-carotene and cancer of the prostate: a case-control study in Kyoto, Japan. *Cancer Res* 1988;48:1331-6.
171. Ramon JM, Bou R, Romea S, et al. Dietary fat intake and prostate cancer risk: a case-control study in Spain. *Cancer Causes Control* 2000;11:679-85.
172. Rodriguez C, McCullough ML, Mondul AM, et al. Calcium, dairy products, and risk of prostate cancer in a prospective cohort of United States men. *Cancer Epidemiol Biomarkers Prev* 2003;12:597-603.
173. Rohrmann S, Platz EA, Kavanaugh CJ, et al. Meat and dairy consumption and subsequent risk of prostate cancer in a US cohort study. *Cancer Causes Control* 2007;18:41-50.
174. Schuurman AG, van den Brandt PA, Dorant E, et al. Animal products, calcium and protein and prostate cancer risk in The Netherlands Cohort Study. *Br J Cancer* 1999;80:1107-13.
175. Severson RK, Nomura AM, Grove JS, et al. A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. *Cancer Res* 1989;49:1857-60.
176. Snowdon DA, Phillips RL, Choi W. Diet, obesity, and risk of fatal prostate cancer. *Am J Epidemiol* 1984;120:244-50.
177. Sonoda T, Nagata Y, Mori M, et al. A case-control study of diet and prostate cancer in Japan: possible protective effect of traditional Japanese diet. *Cancer Sci* 2004;95:238-42.
178. Talamini R, Franceschi S, La Vecchia C, et al. Diet and prostatic cancer: a case-control study in northern Italy. *Nutr Cancer* 1992;18:277-86.
179. Talamini R, La Vecchia C, Decarli A, et al. Nutrition, social factors and prostatic cancer in a Northern Italian population. *Br J Cancer* 1986;53:817-21.
180. Tavani A, Bertuccio P, Bosetti C, et al. Dietary intake of calcium, vitamin D, phosphorus and the risk of prostate cancer. *Eur Urol* 2005;48:27-33.
181. Tavani A, Gallus S, Franceschi S, et al. Calcium, dairy products, and the risk of prostate cancer. *Prostate* 2001;48:118-21.
182. Tseng M, Breslow RA, Graubard BI, et al. Dairy, calcium, and vitamin D intakes and prostate cancer risk in the National Health and Nutrition Examination Epidemiologic Follow-up Study cohort. *Am J Clin Nutr* 2005;81:1147-54.
183. Tzonou A, Signorello LB, Laggiou P, et al. Diet and cancer of the prostate: a case-control study in Greece. *Int J Cancer* 1999;80:704-8.
184. Vlainjac HD, Marinkovic JM, Ilic MD, et al. Diet and prostate cancer: a case-control study. *Eur J Cancer* 1997;33:101-7.
185. Walker M, Aronson KJ, King W, et al. Dietary patterns and risk of prostate cancer in Ontario, Canada. *Int J Cancer* 2005;116:592-8.
186. Lovastatin 5-year safety and efficacy study. Lovastatin Study Groups I through IV. *Arch Intern Med* 1993;153:1079-87.
187. Blais L, Desgagne A, LeLorier J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. *Arch Intern Med* 2000;160:2363-8.

188. Coogan PF, Rosenberg L, Strom BL. Statin use and the risk of 10 cancers. *Epidemiology* 2007;18:213-9.
189. Flick ED, Habel LA, Chan KA, et al. Statin use and risk of prostate cancer in the California Men's Health Study cohort. *Cancer Epidemiol Biomarkers Prev* 2007;16:2218-25.
190. Friis S, Poulsen AH, Johnsen SP, et al. Cancer risk among statin users: a population-based cohort study. *Int J Cancer* 2005;114:643-7.
191. Graaf MR, Beiderbeck AB, Egberts AC, et al. The risk of cancer in users of statins. *J Clin Oncol* 2004;22:2388-94.
192. Jacobs EJ, Rodriguez C, Bain EB, et al. Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort. *Cancer Epidemiol Biomarkers Prev* 2007;16:2213-7.
193. Kaye JA, Jick H. Statin use and cancer risk in the General Practice Research Database. *Br J Cancer* 2004;90:635-7.
194. Murtola TJ, Tammela TL, Lahtela J, et al. Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. *Cancer Epidemiol Biomarkers Prev* 2007;16:2226-32.
195. Platz EA, Leitzmann MF, Visvanathan K, et al. Statin drugs and risk of advanced prostate cancer. *J Natl Cancer Inst* 2006;98:1819-25.
196. Sato S, Ajiki W, Kobayashi T, et al. Pravastatin use and the five-year incidence of cancer in coronary heart disease patients: from the prevention of coronary sclerosis study. *J Epidemiol* 2006;16:201-6.
197. Shannon J, Tewoderos S, Garzotto M, et al. Statins and prostate cancer risk: a case-control study. *Am J Epidemiol* 2005;162:318-25.
198. Boutron-Ruault MC, Marteau P, Lavergne-Slove A, et al. Effects of a 3-mo consumption of short-chain fructo-oligosaccharides on parameters of colorectal carcinogenesis in patients with or without small or large colorectal adenomas. *Nutr Cancer* 2005;53:160-8.
199. Breuer NF, Dommes P, Jaekel S, et al. Fecal bile acid excretion pattern in colonic cancer patients. *Dig Dis Sci* 1985;30:852-9.
200. Breuer NF, Jaekel S, Dommes P, et al. Fecal bile acids in patients with adenomatous polyps of the colon. Case-control study. *Digestion* 1986;34:87-92.
201. Haines A, Hill MJ, Thompson MH, et al. A prospective study of faecal bile acids and colorectal cancer. *Eur J Cancer Prev* 2000;9:317-23.
202. Hikasa Y, Tanida N, Ohno T, et al. Faecal bile acid profiles in patients with large bowel cancer in Japan. *Gut* 1984;25:833-8.
203. Hill MJ, Drasar BS, Williams RE, et al. Faecal bile-acids and clostridia in patients with cancer of the large bowel. *Lancet* 1975;1:535-9.
204. Hill MJ, Melville DM, Lennard-Jones JE, et al. Faecal bile acids, dysplasia, and carcinoma in ulcerative colitis. *Lancet* 1987;2:185-6.
205. Kaibara N, Sasaki T, Ikeguchi M, et al. Fecal bile acids and neutral sterols in Japanese with large bowel carcinoma. *Oncology* 1983;40:255-8.
206. Korpela JT, Adlercreutz H, Turunen MJ. Fecal free and conjugated bile acids and neutral sterols in vegetarians, omnivores, and patients with colorectal cancer. *Scand J Gastroenterol* 1988;23:277-83.
207. Makino T. Fecal bile acid excretion in patients with colon cancer, colon polyp and peptic ulcer. *Tokai J Exp Clin Med* 1984;9:297-305.
208. Meance S, Boutron-Ruault MC, Myara A, et al. Fecal primary bile acids and serum cholesterol are associated with colorectal adenomas. *Dig Dis Sci* 2003;48:1751-7.

209. Mudd DG, McKelvey ST, Norwood W, et al. Faecal bile acid concentration of patients with carcinoma or increased risk of carcinoma in the large bowel. *Gut* 1980;21:587-90.
210. Murray WR, Backwood A, Trotter JM, et al. Faecal bile acids and clostridia in the aetiology of colorectal cancer. *Br J Cancer* 1980;41:923-8.
211. Owen RW, Day DW, Thompson MH. Faecal steroids and colorectal cancer: steroid profiles in subjects with adenomatous polyps of the large bowel. *Eur J Cancer Prev* 1992;1:105-12.
212. Owen RW, Dodo M, Thompson MH, et al. Faecal steroids and colorectal cancer. *Nutr Cancer* 1987;9:73-80.
213. Owen RW, Henly PJ, Thompson MH, et al. Steroids and cancer: faecal bile acid screening for early detection of cancer risk. *J Steroid Biochem* 1986;24:391-4.
214. Perogambros A, Legakis NJ. Faecal bile acids in patients with colon cancer. *Zentralbl Bakteriolog Mikrobiol Hyg [B]* 1982;176:346-8.
215. Reddy BS, Wynder EL. Metabolic epidemiology of colon cancer. Faecal bile acids and neutral sterols in colon cancer patients and patients with adenomatous polyps. *Cancer* 1977;39:2533-9.
216. Tanida N, Hikasa Y, Shimoyama T, et al. Comparison of faecal bile acid profiles between patients with adenomatous polyps of the large bowel and healthy subjects in Japan. *Gut* 1984;25:824-32.
217. Cotterchio M, Kreiger N, Sloan M, et al. Nonsteroidal anti-inflammatory drug use and breast cancer risk. *Cancer Epidemiol Biomarkers Prev* 2001;10:1213-7.
218. Garcia Rodriguez LA, Gonzalez-Perez A. Risk of breast cancer among users of aspirin and other anti-inflammatory drugs. *Br J Cancer* 2004;91:525-9.
219. Harris RE, Chlebowski RT, Jackson RD, et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. *Cancer Res* 2003;63:6096-101.
220. Jacobs EJ, Thun MJ, Connell CJ, et al. Aspirin and other nonsteroidal anti-inflammatory drugs and breast cancer incidence in a large U.S. cohort. *Cancer Epidemiol Biomarkers Prev* 2005;14:261-4.
221. Johnson TW, Anderson KE, Lazovich D, et al. Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. *Cancer Epidemiol Biomarkers Prev* 2002;11:1586-91.
222. Marshall SF, Bernstein L, Anton-Culver H, et al. Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. *J Natl Cancer Inst* 2005;97:805-12.
223. Moorman PG, Grubber JM, Millikan RC, et al. Association between non-steroidal anti-inflammatory drugs (NSAIDs) and invasive breast cancer and carcinoma in situ of the breast. *Cancer Causes Control* 2003;14:915-22.
224. Swede H, Mirand AL, Menezes RJ, et al. Association of regular aspirin use and breast cancer risk. *Oncology* 2005;68:40-7.
225. Terry MB, Gammon MD, Zhang FF, et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. *JAMA* 2004;291:2433-40.
226. Zhang Y, Coogan PF, Palmer JR, et al. Use of nonsteroidal antiinflammatory drugs and risk of breast cancer: the Case-Control Surveillance Study revisited. *Am J Epidemiol* 2005;162:165-70.

227. Bartsch R, Wenzel C, Hussian D, et al. Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study. *BMC Cancer* 2006;6:63.
228. Christodoulou C, Klouvas G, Pateli A, et al. Prolonged administration of weekly paclitaxel and trastuzumab in patients with advanced breast cancer. *Anticancer Res* 2003;23:737-44.
229. Fabi A, Metro G, Ferretti G, et al. Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies. *Breast* 2008;17:499-505.
230. Fountzilas G, Razis E, Tsavdaridis D, et al. Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group. *Clin Breast Cancer* 2003;4:120-5.
231. Garcia-Saenz JA, Martin M, Puente J, et al. Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer. *Clin Breast Cancer* 2005;6:325-9.
232. Gelmon KA, Mackey J, Verma S, et al. Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. *Clin Breast Cancer* 2004;5:52-8; discussion 9-62.
233. Montemurro F, Donadio M, Clavarezza M, et al. Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. *Oncologist* 2006;11:318-24.
234. Stemmler HJ, Kahlert S, Siekiera W, et al. Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC). *Onkologie* 2005;28:582-6.
235. Tripathy D, Slamon DJ, Cobleigh M, et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. *J Clin Oncol* 2004;22:1063-70.
236. Bravi F, Scotti L, Bosetti C, et al. Food groups and endometrial cancer risk: a case-control study from Italy. *Am J Obstet Gynecol* 2008.
237. Hirose K, Niwa Y, Wakai K, et al. Coffee consumption and the risk of endometrial cancer: Evidence from a case-control study of female hormone-related cancers in Japan. *Cancer Sci* 2007;98:411-5.
238. Jain MG, Howe GR, Rohan TE. Nutritional factors and endometrial cancer in Ontario, Canada. *Cancer Control* 2000;7:288-96.
239. Koizumi T, Nakaya N, Okamura C, et al. Case-control study of coffee consumption and the risk of endometrial endometrioid adenocarcinoma. *Eur J Cancer Prev* 2008;17:358-63.
240. Levi F, Franceschi S, Negri E, et al. Dietary factors and the risk of endometrial cancer. *Cancer* 1993;71:3575-81.
241. Petridou E, Kedikoglou S, Koukoulomatis P, et al. Diet in relation to endometrial cancer risk: a case-control study in Greece. *Nutr Cancer* 2002;44:16-22.
242. Shimazu T, Inoue M, Sasazuki S, et al. Coffee consumption and risk of endometrial cancer: a prospective study in Japan. *Int J Cancer* 2008;123:2406-10.
243. Stensvold I, Jacobsen BK. Coffee and cancer: a prospective study of 43,000 Norwegian men and women. *Cancer Causes Control* 1994;5:401-8.
244. Terry P, Vainio H, Wolk A, et al. Dietary factors in relation to endometrial cancer: a nationwide case-control study in Sweden. *Nutr Cancer* 2002;42:25-32.